Hepatic Encephalopathy Clinical Trial
Official title:
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
The aim of the current study is to determine whether rifaximin or lactulose is more
effective in preventing the development of severe hepatic encephalopathy in hospitalized
patients with cirrhosis and new onset kidney failure.
Subjects will be randomly assigned to one of two treatment groups:
Group A: Lactulose 20g dose titrated to 2-3 soft-formed bowel movements per day Group B:
Rifaximin 550mg tablet twice daily.
Subjects will be followed daily for two weeks or until hospital discharge. Treatment success
is defined as prevention of grade 3 or 4 HE during hospitalization.
Hepatic Encephalopathy (HE) is a reversible neuropsychiatric syndrome that develops in
patients with cirrhosis due to the accumulation of a variety of toxic substances that are
produced from bacteria in the gastrointestinal tract. It is characterized by slowing of
function of the brain function and ranges in severity from mild cognitive impairment (grade
1), presence of a shaking tremor called asterixis (grade 2), lethargy but arousable state
(grade 3), and coma (grade 4). Decreased kidney function exacerbates the condition, and
hospitalized patients with cirrhosis with new onset kidney failure are at risk for the
development of severe HE.
Possible treatments for HE include lactulose and antibiotics. Lactulose reduces the
production of many of the toxins by the bacteria, and antibiotics work by reducing the
number of bacteria in the gastrointestinal tract. Rifaximin is an antibiotic that is an
antibiotic that is not absorbed, possesses a wide antibacterial spectrum, and was approved
by the Food and Drug Administration in 3/2010 for prevention of relapse for patients with
recurrent severe hepatic encephalopathy. The aim of the current study is to determine
whether rifaximin or lactulose is more effective in preventing the development of severe
hepatic encephalopathy in hospitalized patients with cirrhosis and new onset kidney failure.
To determine whether rifaximin or lactulose is more effective in preventing severe HE,
seventy consecutive hospitalized patients with cirrhosis and new onset kidney failure will
be recruited. New onset kidney failure will defined as a progressive and sustained increase
in serum creatinine >0.5mg/dl from baseline to a value of 2.0mg/dl or greater within 3 days.
Subjects will be randomly assigned to one of two treatment groups:
Group A: Lactulose 20g dose titrated to 2-3 soft-formed bowel movements per day Group B:
Rifaximin 550mg tablet twice daily. Subjects will be followed daily for two weeks or until
hospital discharge. Severity of hepatic encephalopathy will be graded by physical
examination, review of hospital chart, and performance of standard paper and pencil tests
that evaluates the ability to concentrate. In addition, approximately one tablespoon will be
drawn twice a week at every 3 to 4 day for ammonia level and other toxins. A sample of
breath will also be collected by having the subjects breathe into a collection bag to
measure substances that determine whether there are bacteria present in the small intestine.
Treatment success is defined as prevention of grade 3 or 4 HE during hospitalization.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
| Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
| Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
| Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
| Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
| Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
| Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
| Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
| Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
| Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
| Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
| Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
| Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
| Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
| Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A | |
| Completed |
NCT01008293 -
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
|
Phase 2/Phase 3 |